Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$13.70 USD
+0.08 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $13.69 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Perspective Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 11 | 10 | 10 |
Cost Of Goods | 0 | 0 | 6 | 5 | 5 |
Gross Profit | 1 | 0 | 5 | 5 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 0 | 12 | 9 | 9 |
Income After Depreciation & Amortization | -41 | 0 | -7 | -3 | -3 |
Non-Operating Income | -8 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -49 | 0 | -7 | -3 | -3 |
Income Taxes | -3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -47 | 0 | -7 | -3 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -47 | 0 | -7 | -3 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -40 | 0 | -7 | -3 | -3 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -41 | 0 | -7 | -3 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.76 | 14.20 | 10.38 | 6.76 | 6.70 |
Diluted EPS Before Non-Recurring Items | -1.40 | -0.50 | -0.30 | -0.50 | -0.80 |
Diluted Net EPS (GAAP) | -1.70 | -0.50 | -0.50 | -0.30 | -0.50 |
Fiscal Year end for Perspective Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.33 | -4.90 | 2.19 | 2.09 |
Cost Of Goods | NA | 0.00 | -4.86 | 1.45 | 1.84 |
Gross Profit | NA | 0.33 | -4.90 | 0.74 | 0.25 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.33 | 7.77 | 11.27 | 11.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -13.00 | -12.67 | -10.53 | -11.37 |
Non-Operating Income | NA | 1.21 | -8.99 | 0.20 | 0.30 |
Interest Expense | NA | 0.03 | 0.02 | 0.01 | 0.03 |
Pretax Income | NA | -11.82 | -16.83 | -10.36 | -11.11 |
Income Taxes | NA | 0.00 | 7.85 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.82 | -24.68 | -10.36 | -11.11 |
Extras & Discontinued Operations | NA | -0.46 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.28 | -24.68 | -10.36 | -11.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 49.51 | NA | 28.06 | 28.00 |
Diluted EPS Before Non-Recurring Items | NA | -0.20 | NA | -0.40 | -0.40 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.90 | -0.40 | -0.40 |